v3.25.1
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Total
Balance at Jun. 30, 2023 $ 29,487 $ 29,941,873 $ (22,522,649) $ (118,224) $ 7,330,487
Balance (in shares) at Jun. 30, 2023 29,487,508        
Stock options expense   104,502     104,502
Grant of restricted common stock $ 380 (380)      
Grant of restricted common stock (in shares) 380,000        
Forfeited restricted common stock $ (200) 200      
Forfeited restricted common stock (in shares) (200,000)        
Repurchase of common stock $ (186) (521,838)     (522,024)
Repurchase of common stock (in shares) (186,148)        
Common stock issued upon exercise of stock options $ 71 (71)      
Common stock issued upon exercise of stock options (in shares) 71,050        
Common stock issued for acquisition of Scite $ 2,729 6,546,905     6,549,634
Common stock issued for acquisition of Scite (in shares) 2,729,014        
Modification cost of accelerated vesting of restricted common stock   20,949     20,949
Restricted common stock expense   1,603,820     1,603,820
Net Income (Loss)     (965,370)   (965,370)
Foreign currency translation       6,261 6,261
Balance at Mar. 31, 2024 $ 32,281 37,695,960 (23,488,019) (111,963) 14,128,259
Balance (in shares) at Mar. 31, 2024 32,281,424        
Balance at Dec. 31, 2023 $ 32,620 37,607,895 (23,564,320) (112,821) 13,963,374
Balance (in shares) at Dec. 31, 2023 32,619,598        
Stock options expense   42,788     42,788
Forfeited restricted common stock $ (200) 200      
Forfeited restricted common stock (in shares) (200,000)        
Repurchase of common stock $ (159) (453,117)     (453,276)
Repurchase of common stock (in shares) (159,044)        
Common stock issued upon exercise of stock options $ 20 (20)      
Common stock issued upon exercise of stock options (in shares) 20,870        
Restricted common stock expense   498,214     498,214
Net Income (Loss)     76,301   76,301
Foreign currency translation       858 858
Balance at Mar. 31, 2024 $ 32,281 37,695,960 (23,488,019) (111,963) 14,128,259
Balance (in shares) at Mar. 31, 2024 32,281,424        
Balance at Jun. 30, 2024 $ 32,295 38,089,958 (26,309,246) (118,819) 11,694,188
Balance (in shares) at Jun. 30, 2024 32,295,373        
Stock options expense   146,751     146,751
Grant of restricted common stock $ 590 (590)      
Grant of restricted common stock (in shares) 590,000        
Forfeited restricted common stock $ (229) 229      
Forfeited restricted common stock (in shares) (228,584)        
Repurchase of common stock $ (300) (908,093)     $ (908,393)
Repurchase of common stock (in shares) (300,596)        
Common stock issued upon exercise of stock options $ 49 (49)      
Common stock issued upon exercise of stock options (in shares) 48,927       128,821
Restricted common stock expense   1,400,199     $ 1,400,199
Net Income (Loss)     (1,094,760)   (1,094,760)
Foreign currency translation       (6,855) (6,855)
Balance at Mar. 31, 2025 $ 32,405 38,728,405 (27,404,006) (125,674) 11,231,130
Balance (in shares) at Mar. 31, 2025 32,405,120        
Balance at Dec. 31, 2024 $ 32,640 38,836,646 (27,620,476) (122,350) 11,126,460
Balance (in shares) at Dec. 31, 2024 32,640,407        
Stock options expense   58,706     58,706
Repurchase of common stock $ (246) (702,869)     (703,115)
Repurchase of common stock (in shares) (246,707)        
Common stock issued upon exercise of stock options $ 11 (11)      
Common stock issued upon exercise of stock options (in shares) 11,420        
Restricted common stock expense   535,933     535,933
Net Income (Loss)     216,470   216,470
Foreign currency translation       (3,324) (3,324)
Balance at Mar. 31, 2025 $ 32,405 $ 38,728,405 $ (27,404,006) $ (125,674) $ 11,231,130
Balance (in shares) at Mar. 31, 2025 32,405,120